Therapeutic Value of Vitamin C Now Linked to Cancer Treatment

A recent series of studies reported by Science Magazine online indicated the need to further research mega-dose vitamin C, usually delivered intravenously, as an adjunct for cancer treatments with normal treatment resistance due to KRAS or BRAF gene mutations. Half or more colorectal (colon), lung, and ovarian cancer cells contain those mutated genes that manage to repel chemotherapeutic attempts at targeting them. The laboratory and animal studies convinced researchers that there is potential for at least applying mega-dose vitamin C therapy with conventional chemotherapy to lead the charge at disabling those genes. This was a mainstream medical research endeavor, not an alternative treatment study. But some oncologists lauded the study and feel compelled to start using mega-dose vitamin C therapies on cancer patients with conventional oncology's “standard of care” chemotherapy.